Search

Displaying results 6901 - 6910 of 8974 in total
  1. Drug

    Chlorophyll B

    go.drugbank.com/drugs/DB04506
    Experimental

    Its salts are essential in nutrition, being required for the activity of many enzymes, especially those concerned with oxidative phosphorylation.

    Categories: Heterocyclic Compounds with 4 or More Rings
  2. Drug

    Vosilasarm

    go.drugbank.com/drugs/DB13939
    Investigational

    RAD140 is an investigational selective androgen receptor modulator (SARM) for the treatment of conditions such as muscle wasting and breast cancer.

  3. Drug

    ISIS 104838

    go.drugbank.com/drugs/DB16201
    Investigational

    ISIS 104838 is under investigation in clinical trial NCT00048321 (ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis).

  4. Drug

    Dalcinonacog alfa

    go.drugbank.com/drugs/DB17707
    Investigational

    It is being investigated for the treatment of hemophilia B.[A259058]

  5. Drug

    GT-AS

    go.drugbank.com/drugs/DB17883
    Experimental

    GT-AS recombinant adeno-associated virus serotype 9 vector containing the transgene UBE3A encoding for ubiquitin protein ligase E3A/E6-AP.

  6. Drug

    OTOF-GT

    go.drugbank.com/drugs/DB18129
    Investigational

    OTOF-GT is a dual vector AAV gene therapy being investigated for the restoration of hearing loss associated with otoferlin deficiency.

  7. Drug

    TTX-MC138

    go.drugbank.com/drugs/DB18628
    Investigational

    [L48335] It is under investigation for the treatment of various metastatic cancers.

  8. Drug

    Rilvegostomig

    go.drugbank.com/drugs/DB18991
    Investigational

    Rilvegostomig is under investigation in clinical trial NCT06109779 (Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (Artemide-biliary01)).

  9. Drug

    Lefitolimod

    go.drugbank.com/drugs/DB15061
    Investigational

    Lefitolimod is under investigation in clinical trial NCT03837756 (Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV).

  10. Drug

    DP-VPA

    go.drugbank.com/drugs/DB05821
    Investigational

    DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure frequency.